Micro Cap Stocks – Chelsea Therapeutics International Ltd, ZIOPHARM Oncology Inc, The Goldfield Corporation, Aastrom Biosciences Inc
New York, NY – (Net PR News) – 03/27/2013 – smartOTC is the premiere destination for Investors and novices alike who wish to receive information on fast moving OTC stocks and undiscovered companies. Most of these companies are considered penny stocks and trade on the Pink Sheet or OTC BB market. Our daily alerts help investors cut their research time in half as we send out small cap and penny stock alerts that are displaying signs of a potential rally.
Sign up For Our No. 1 Rated Stock Newsletter to make Huge Profits http://www.smartotc.com
SmartOTC brings a special trend analysis of these stocks: Chelsea Therapeutics International Ltd (NASDAQ:CHTP), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), The Goldfield Corporation (NYSEAMEX:GV), Aastrom Biosciences, Inc. (NASDAQ:ASTM)
Chelsea Therapeutics International Ltd (NASDAQ:CHTP) opened at the price of $2.07, along with 67.04 million shares outstanding and touched its highest price of the day at $2.17 recently. The stock is trading at the price of $2.00 by scoring +8.40% at 2:07 PM.
The stock’s previous performance of one month showed that it gained almost 23.46%. In the previous 3 months, it scored +142.67%. During its current trading session, the stock gained a volume of 5.37 million shares up-till now, which is higher than its average volume of 2.42 million shares. Chelsea Therapeutics International, Ltd., a development-stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products.
What was the Moving Force behind CHTP’s Bullish Run? Read This Research Report on CHTP
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock recently hit its highest price at $1.91, starting its day trade with a price of $1.77 and reported a decrease of -8.35%. Its most recent trading price was $1.66 at 2:15 PM. 52 week price range of the company is $1.66 – $6.33, while today, up until 2:15 PM, its minimum price was $1.66. ZIOP recently added a volume of 4.87 million shares, versus its average volume of 2.91 million shares. ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a DNA alkylating agent, is under Phase III clinical trial for the treatment of first-line metastatic soft tissue sarcoma and is in Phase III clinical trial for first-line metastatic small cell lung cancer.
Has ZIOP Found The Bottom and Ready To Move Up? Find Out Here
The Goldfield Corporation (NYSEAMEX:GV) remained among the bears of the day during the early hours of trading, as it went down -13.96% recently. Beta value of the stock remained at 1.55 points, while its earnings per share were $0.37.
During the last 5 day’s, it lost -2.17%, while its last one month’s performance stands at 25.35%. The company’s traded volume is 3.73 million shares, as compared to its average volume of 1.36 million shares. The Goldfield Corporation, through its subsidiaries, engages in the electrical construction and real estate development business activities in the United States. Its electrical construction business includes the construction of transmission lines, concrete foundations, distribution systems and substations, and other electrical installation services for utility systems; industrial and specialty projects; and overhead fiber optic cable installation.
Has GV Found The Bottom And Ready To Gain Momentum? Find Out Here
Aastrom Biosciences, Inc. (NASDAQ:ASTM) is trading with a fall of -38.26% along with the exchange price of $0.710 up till now while its introductory price for today was $0.89.
Company’s 6 month’s performance lost -56.44% while in its last 5 days its performance remained in the red with theplummet of -39.32%. Today, up until 2:22 PM, its minimum price was $0.70. ASTM recently added a volume of 3.55 million shares, versus its average volume of 472,752 shares. Aastrom Biosciences, Inc. (ASTM) announced a strategic change in its research and development programs to focus on the clinical development of its lead product, ixmyelocel-T, for the treatment of dilated cardiomyopathy (DCM).
Why Should Investors Buy ASTM After the Recent Fall? Just Go Here and Find Out
smartOTC is the premiere destination for Investors and novice alike who wish to receive information on fast moving OTC penny stocks and undiscovered companies. We are a marketing firm that releases paid reports on undiscovered companies looking to tell their stories. Most of these companies are considered penny stocks and trade on the Pink Sheet or OTC BB market. Our daily alerts help investors cut their research time in half as we send out small cap and penny stock alerts that are displaying signs of a potential rally.
While penny stocks pose a much more significant risk factor compared to large cap stocks, their lure of quick gains makes it a trading choice for many small time and beginner investors. There is nothing wrong with investments into penny stocks, the best advice is to do your own research and consult with your own financial professional. smartOTC reports and alerts should only be used as a starting point for your own due diligence.
PLEASE NOTE WELL: This report/release/advertisement is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation.
Smartotc.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The disclaimer is to be read and fully understood before using our site, or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Read Our Full Disclaimer at http://www.smartotc.com/disclaimer